Mild cognitive impairment in older adults

Current Psychiatry Reports

Volumn 14, Issue 4, 2012, Pages 320-327

  Geda, Yonas E ^a  

^a MAYO CLINIC   (United States)

Author keywords

Age associated cognitive decline; Age associated memory impairment; Aging; Asymptomatic Alzheimer's disease; Benign and malignant forgetfulness; Cognitive impairment no dementia; Dementia; Dementia of Alzheimer's type; Mild cognitive impairment; Mild neurocognitive decline; Neuropsychiatric symptoms; Questionable dementia

Indexed keywords

ALPHA TOCOPHEROL; CHOLINERGIC RECEPTOR STIMULATING AGENT; DONEPEZIL; MEMANTINE; PLACEBO;

ALZHEIMER DISEASE; ARTICLE; BRADYCARDIA; CLINICAL EVALUATION; DEMENTIA; DISEASE CLASSIFICATION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL MOTILITY; HUMAN; MENTAL HEALTH; MILD COGNITIVE IMPAIRMENT; MOLECULAR IMAGING; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; PHYSICAL EXAMINATION; PSYCHOMETRY; PUBLIC HEALTH; SEX DIFFERENCE; SIDE EFFECT; STOMACH ACID SECRETION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; DISEASE PROGRESSION; HUMANS; INCIDENCE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; PREVALENCE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; SEX DISTRIBUTION; UNITED STATES;

EID: 84865660409     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-012-0291-x     Document Type: Article

References (63)

1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303-8. (Pubitemid 29120227)
2. Reisberg B, Ferris SH, de Leon MJ, Crook T. Global Deterioration Scale (GDS). Psychopharmacol Bull. 1988;24:661-3.
3. Reisberg B, Ferris SH, de Leon MJ, et al. Stage-specific behavioral, cognitive, and in vivo changes in community residing subjects with age-associated memory impairment and primary degenerative dementia of the Alzheimer's type. Drug Development Research. 1988;15:101-114. (Pubitemid 19151267)
4. Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology. 1991;41:1006-9.
5. Kral VA. Senescent forgetfulness: benign and malignant. Can Med Assoc J. 1962;86:257-60.
6. Crook T, Bartus RT, Ferris SH, Whitehouse P, Cohen GD, Gershon S. Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change -report of a National Institute of Mental Health work group. Development Neuropsychol. 1986;2:261-76.
7. Levy R. Aging-associated cognitive decline. Working party of the International Psychogeriatric Association in collaboration with the World Health Organization. Int Psychogeriatr. 1994;6:63-8.
8. American Psychiatric Association, American Psychiatric Association. Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Association; 1994.
9. Blackford RC, La Rue A. Criteria for diagnosing age-associated memory impairment: proposed improvements from the field. Development Neuropsychol. 1989;5:295-306.
10. Devanand DP, Folz M, Gorlyn M, Moeller JR, Stern Y. Questionable dementia: clinical course and predictors of outcome. J Am Geriatr Soc. 1997;45:321-8. (Pubitemid 27114305)
11. Reisberg B, Prichep L, Mosconi L, John ER, Glodzik-Sobanska L, Boksay I, et al. The pre-mild cognitive impairment, subjective cognitive impairment stage of Alzheimer's disease. Alzheimers Dement. 2008;4 Suppl 1:S98-108.
12. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004;61:59-66. (Pubitemid 38067415)
13. Petersen RC. Clinical practice. Mild cognitive impairment. N Engl J Med. 2011;364:2227-34. This reference is the most up-todate review, particularly on advances made in the area of biomarkers and neuroimaging research pertinent to MCI and AD.
14. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L,Wahlund LO, et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256:240-6. (Pubitemid 39222993)
15. Williams JW, United States. Agency for Healthcare Research and Quality. Duke University Evidence-based Practice Center. Preventing Alzheimer's disease and cognitive decline. Evidence report/technology assessment, vol no 193. Agency for Healthcare Research and Quality, Rockville, MD; 2010.
16. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337-42. (Pubitemid 28402270)
17. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007;3:186-91. (Pubitemid 46825511)
18. Rice DP, Fox PJ, Max W, Webber PA, Lindeman DA, Hauck WW, et al. The economic burden of Alzheimer's disease care. Health Aff (Millwood). 1993;12:164-76. (Pubitemid 23220072)
19. Geda YE, Negash S, Petersen RC. Memory disorders. In: Agronin ME, Maletta GJ (eds). Principles and practice of geriatric psychiatry. Lippincott Williams & Wilkins, Philadelphia, PA; 2006.
20. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985-92. (Pubitemid 33143977)
21. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280-92. This article describes AA-NIA research criteria for asymptomatic AD. Very useful in a research setting.
22. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270-9. This article describes the criteria for MCI due to AD.
23. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr. CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-9. This article describes the AA-NIA criteria for the diagnosis of dementia due to AD. Involvement of memory domain does not have a central place in the diagnostic criteria for dementia of Alzheimer's type. This is in sharp contrast with the DSM-IV criteria for dementia of Alzheimer's type.
24. Ganguli M, Blacker D, Blazer DG, Grant I, Jeste DV, Paulsen JS, et al. Classification of neurocognitive disorders in DSM-5: a work in progress. Am J Geriatr Psychiatry. 2011;19:205-10. This is a very important reference in order to understand the ongoing work of the DSM-5 task force on neurocognitive disorders, including MCI.
25. Molano J, Boeve B, Ferman T, Smith G, Parisi J, Dickson D, et al. Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain. 2010;133:540-56.
26. Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology. 2004;63:115-21. (Pubitemid 38943788)
27. Hanninen T, Hallikainen M, Tuomainen S, Vanhanen M, Soininen H. Prevalence of mild cognitive impairment: a population-based study in elderly subjects. Acta Neurol Scand. 2002;106:148-54.
28. Larrieu S, Letenneur L, Orgogozo JM, Fabrigoule C, Amieva H, Le Carret N, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology. 2002;59:1594-9. (Pubitemid 35387068)
29. Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF, et al. The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic study of aging. Neurology. 2012;78:342-51. This reference contains the most recent population-based estimates of the incidence of MCI. Thearticle has reported unexpected differences in incidence of MCI by sex, i.e., the incidence of MCI is higher in men than in women.
30. Sackett DL. Bias in analytic research. J Chronic Dis. 1979;32:51-63.
31. Petersen RC, Roberts RO, Knopman DS, Geda YE, Cha RH, Pankratz VS, et al. Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic study of aging. Neurology. 2010;75:889-97.
32. Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF, et al. The Mayo Clinic study of aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30:58-69. (Pubitemid 351311727)
33. Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C, et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular health study cognition study: part 1. Arch Neurol. 2003;60:1385-9. (Pubitemid 37248799)
34. Kumar R, Dear KB, Christensen H, Ilschner S, Jorm AF, Meslin C, et al. Prevalence of mild cognitive impairment in 60-to 64-year-old community-dwelling individuals: the personality and total health through Life 60+ Study. Dement Geriatr Cogn Disord. 2005;19:67-74. (Pubitemid 40868030)
35. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379-88. (Pubitemid 40958434)
36. Tierney MC, Szalai JP, Snow WG, Fisher RH, Tsuda T, Chi H, et al. A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology. 1996;46:149-54. (Pubitemid 26156121)
37. Daly E, Zaitchik D, Copeland M, Schmahmann J, Gunther J, Albert M. Predicting conversion to Alzheimer disease using standardized clinical information. Arch Neurol. 2000;57:675-80. (Pubitemid 30252802)
38. Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study. Neurology. 2001;56:37-42. (Pubitemid 32059649)
39. Benton A, Hamsher K. Multilingual aphasia examination manual. Iowa City: University of Iowa; 1978.
40. Mesulam MM. From sensation to cognition. Brain. 1998;121:1013-52.
41. Kokmen E, Naessens JM, Offord KP. A short test of mental status: description and preliminary results.Mayo Clin Proc. 1987;62:281-8.
42. Tang-Wai DF, Knopman DS, Geda YE, Edland SD, Smith GE, Ivnik RJ, et al. Comparison of the short test of mental status and the mini-mental state examination in mild cognitive impairment. Arch Neurol. 2003;60:1777-81. (Pubitemid 37521636)
43. Ferrarini L, Frisoni GB, Pievani M, Reiber JH, Ganzola R, Milles J. Morphological hippocampal markers for automated detection of Alzheimer's disease and mild cognitive impairment converters in magnetic resonance images. J Alzheimers Dis. 2009;17:643-59.
44. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-19. (Pubitemid 38269583)
45. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446-52. (Pubitemid 44214969)
46. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006;129:2856-66. (Pubitemid 44684508)
47. Klunk WE, Mathis CA, Price JC, Lopresti BJ, DeKosky ST. Twoyear follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006;129:2805-7. (Pubitemid 44684503)
48. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009;66:1469-75.
49. Petersen RC. Mild cognitive impairment clinical trials. Nat Rev Drug Discov. 2003;2:646-53. (Pubitemid 37361768)
50. KnappMJ, Knopman DS, Solomon PR, PendleburyWW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine study group. JAMA. 1994;271:985-91. (Pubitemid 24099918)
51. Rogers SL, FarlowMR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil study group. Neurology. 1998; 50:136-45.
52. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999;318:633-8.
53. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 study group. BMJ. 2000;321:1445-9.
54. Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry. 2004;161:532-8. (Pubitemid 38326109)
55. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-41. (Pubitemid 36384100)
56. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317-24. (Pubitemid 38101604)
57. Lockhart BP, Lestage PJ. Cognition enhancing or neuroprotective compounds for the treatment of cognitive disorders: why? when? which? Exp Gerontol. 2003;38:119-28. (Pubitemid 36110506)
58. Hayes TL, Larimer N, Adami A, Kaye JA. Medication adherence in healthy elders: small cognitive changes make a big difference. J Aging Health. 2009;21:567-80.
59. Lloret A, Badia MC, Mora NJ, Pallardo FV, Alonso MD, Vina J. Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. J Alzheimers Dis. 2009;17:143-9.
60. Miller 3rd ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37-46.
61. Geda YE, Petersen RC. Clinical trials in mild cognitive impairment. In: Gauthier S, Cummings J (eds). Alzheimer's disease and related disorders. 2nd edn. Martin Dunitz, London; 2001.
62. Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology. 2004;63:651-7. (Pubitemid 39100820)
63. Diniz BS, Pinto Jr. JA, Gonzaga ML, Guimaraes FM, Gattaz WF, Forlenza OV. To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 2009;259:248-56.